Sign In
Buy SCPH
$5.67
+0 (+0%)
At Close: Nov 17, 2025
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of s
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VTLE and SCPH on Behalf of Shareholders
10:32am, Tuesday, 26'th Aug 2025
NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breac
SCPH Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of scPharmaceuticals to MannKind
03:58pm, Monday, 25'th Aug 2025
MONSEY, N.Y., Aug. 25, 2025 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the sale of scPharmaceuticals, Inc. (Nasdaq: SCPH) (“SCPH”) to MannKind Corpora
SCPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of scPharmaceuticals Inc. Is Fair to Shareholders
09:18am, Monday, 25'th Aug 2025
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of scPharmaceuticals Inc. (NASDAQ: SCPH) to MannKind Corporation is fair to scPharmaceutical
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating scPharmaceuticals (NASDAQ: SCPH) for possible breaches of fiduciary duty and other violations of law in its transaction with MannKind. Click
DANBURY, Conn. and BURLINGTON, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) and scPharmaceuticals Inc. (Nasdaq: SCPH) today announced the signing of a definitive merger
scPharmaceuticals Receives Notice of Allowances of Multiple US Patent Applications Covering SCP-111
08:30am, Thursday, 14'th Aug 2025
BURLINGTON, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through pat
scPharmaceuticals Inc. (SCPH) Q2 2025 Earnings Call Transcript
02:09pm, Friday, 08'th Aug 2025
scPharmaceuticals Inc. (NASDAQ:SCPH ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants John Mohr - Senior Vice President of Clinical Development & Medical Affairs John H
scPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Lags Revenue Estimates
07:01pm, Thursday, 07'th Aug 2025
scPharmaceuticals, Inc. (SCPH) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.44 per share a year ago.
scPharmaceuticals Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update
04:01pm, Thursday, 07'th Aug 2025
Generated net FUROSCIX ® revenue of $16 million in the second quarter of 2025; up 99% over Q2 2024
scPharmaceuticals to Announce Second Quarter 2025 Financial Results After the Market Close on August 7, 2025
04:01pm, Thursday, 31'st Jul 2025
BURLINGTON, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovat
scPharmaceuticals (SCPH) Soars 8.8%: Is Further Upside Left in the Stock?
09:16am, Friday, 25'th Jul 2025
scPharmaceuticals (SCPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength do
scPharmaceuticals: Furoscix Sales To Accelerate Throughout 2025
07:29am, Thursday, 22'nd May 2025
Shares of scPharmaceuticals have lost 37% over the past 3 years and are down 11% in 2025. Furoscix's subcutaneous administration offers the potential to keep heart failure patients at home longer and
scPharmaceuticals Inc. (SCPH) Q1 2025 Earnings Call Transcript
12:15am, Thursday, 15'th May 2025
scPharmaceuticals Inc. (NASDAQ:SCPH ) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants William Thorpe - Investor Relations John Tucker - Chief Executive Officer Steve Pars
